Can a Four-Drug cocktail tame pancreatic cancer? a Real-World trial seeks answers

NCT ID NCT07723261

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study follows about 70 people with metastatic pancreatic cancer who are receiving NalIriFOx as their first treatment. Researchers are collecting real-world data to see how well the drug combination controls the disease and what side effects occur. The goal is to understand whether this regimen offers meaningful long-term benefits in everyday clinical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of liposomal irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin (NalIriFOx)
What this could lead to
If the data show strong real-world effectiveness, this could support NalIriFOx as a standard first-line option for metastatic pancreatic cancer.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects from the chemotherapy combination can be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • 2nd Oncology Department, Metropolitan Hospital

    RECRUITING

    Athens, 185 47, Greece

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Attikon University General Hospital

    RECRUITING

    Athens, 124 62, Greece

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • General Hospital Agios Andreas

    RECRUITING

    Pátrai, 263 32, Greece

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • General Oncology Hospital Agioi Anargyroi

    RECRUITING

    Athens, 145 64, Greece

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • HYGEIA Hospital

    RECRUITING

    Athens, 151 23, Greece

  • HYGEIA Hospital

    RECRUITING

    Athens, 151 23, Greece

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ippokratio

    RECRUITING

    Athens, Greece

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Larissa University General Hospital

    RECRUITING

    Larissa, Greece

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Thessaloniki General Hospital "George Papanikolaou"

    RECRUITING

    Thessaloniki, 570 10, Greece

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.